Abstract Number: 171 • 2012 ACR/ARHP Annual Meeting
Disease Modifying Agents Combined with Isoniazid for Latent Tuberculosis in Patients with Rheumatic Diseases
Background/Purpose: Reactivation of latent tuberculosis (LTB) has been described with the use of anti-TNF for the treatment of rheumatic diseases. Combined treatment of isoniazid (INH)…Abstract Number: 172 • 2012 ACR/ARHP Annual Meeting
A Systematic Review and Meta-Analysis of Antibiotic Treatment for Reactive Arthritis
Background/Purpose: Although bacterial infections are a common precipitant, it is unclear whether antibiotic treatment is effective for reactive arthritis. The purpose of this study was…Abstract Number: 173 • 2012 ACR/ARHP Annual Meeting
Latent Tuberculosis Screening and Treatment in Rheumatoid Arthritis Patients Eligible for Anti-TNF Therapy in Endemic Areas: Does It Work?
Background/Purpose: Background: Current recommendations for latent tuberculosis infection (LTB) screening and treatment in patients eligible for anti-TNF agents are not well established in endemic regions.…Abstract Number: 174 • 2012 ACR/ARHP Annual Meeting
Prevalence, Risk Factors, and Functional Impact of Arthralgias Among Patients with Chronic Hepatitis C Virus Infection
Background/Purpose: The prevalence, risk factors and functional impact of joint pain are not well described in chronic hepatitis C virus (HCV)-infected patients, particularly in the…Abstract Number: 175 • 2012 ACR/ARHP Annual Meeting
The Impact of Hepatitis Screening On Diagnosis and Treatment in Rheumatoid Arthritis
Background/Purpose: Hepatitis testing is an important pre-requisite to the diagnosis and treatment of patients with rheumatic disease. Joint symptoms may be a manifestation of acute…Abstract Number: 176 • 2012 ACR/ARHP Annual Meeting
Prevalence and Associations of Hepatitis C Arthritis in Chronic Hepatitis C Virus Infection
Background/Purpose: Chronic infection with hepatitis C virus (HCV) has been reported to cause inflammatory arthritis and/or fibromyalgia. Case series of patients with HCV-associated arthritis have…Abstract Number: 177 • 2012 ACR/ARHP Annual Meeting
Antibodies to Citrullinated Peptides in Tuberculosis
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease characterized by symmetric polyarthritis, rheumatoid factor positivity (RF) in the majority of patients, and bone erosions shown…Abstract Number: 178 • 2012 ACR/ARHP Annual Meeting
Intravenous Immunoglobulin in Parvovirus B19 Mediated Pure Red Cell Aplasia: A Retrospective Study in 10 Patients and a Review of 123 Cases
Background/Purpose: The efficacy of intravenous immunoglobulin (IVIg) therapy in patients with pure red cell aplasia (PRCA) related to human parvovirus B19 (HPV-B19) infection is mainly…Abstract Number: 179 • 2012 ACR/ARHP Annual Meeting
Evaluation of Anakinra Therapy in Seven Adults After Suboptimal Response to Etanercept Therapy for Tumor Necrosis Factor Receptor-Associated Periodic Fever Syndrome
Background/Purpose: Tumor Necrosis Factor Receptor-Associated Periodic Fever Syndrome (TRAPS) is an autoinflammatory disease inherited in an autosomal dominant fashion. TRAPS develops secondary to mutations in…Abstract Number: 180 • 2012 ACR/ARHP Annual Meeting
Safety of Canakinumab in a Large Cohort of Patients with Cryopyrin-Associated Periodic Syndrome: Results From the ß-Confident Registry
Background/Purpose: Cryopyrin-associated periodic syndrome (CAPS) is an extremely rare autoinflammatory disorder associated with overproduction of interleukin-1β (IL-1β). Canakinumab, a fully human, selective, anti-IL-1β monoclonal antibody,…Abstract Number: 181 • 2012 ACR/ARHP Annual Meeting
Thiopurine S-Methyltransferase Levels in Patients with Behçet’s Disease
Background/Purpose: Azathioprine (AZA) is an immunosuppressive agent which is widely used not only for the treatment of Behcet’s disease (BD), but also for the treatment…Abstract Number: 182 • 2012 ACR/ARHP Annual Meeting
Comprehensive Analysis of Protein Expression in Peripheral Blood Mononuclear Cells From Patients with Behcet’s Disease
Background/Purpose: To elucidate the pathophysiology of Behcet’s disease (BD) and to establish biomarkers for the disease, we comprehensively analyzed protein expression of peripheral blood mononuclear…Abstract Number: 183 • 2012 ACR/ARHP Annual Meeting
A Strong Association Between HLA-A*26 and Behçet’s Syndrome in Japanese Patients: From Two-Center Cohort Study of Behçet’s Syndrome
Background/Purpose: An association between Behçet’s Syndrome (BS) and HLA-B*51 is widely reported among many different ethnic groups. Recently, a few reports from Taiwan, Greece and…Abstract Number: 184 • 2012 ACR/ARHP Annual Meeting
The Retrospective Review of 39 Intestinal Behcet’s Disease Focusing On the Requirement for the Immunosuppresive Drugs Other Than Corticosteroid
Background/Purpose: To examine the demography, clinical characteristics, features of intestinal lesions, treatment, and prognosis in patients with the intestinal Behcet’s disease currently followed at a…Abstract Number: 185 • 2012 ACR/ARHP Annual Meeting
Long-Term Efficacy and Safety of Tumour Necrosis Factor Antagonists for Patients with Behçet’s Disease with Uveitis As Main Involvement
Background/Purpose: To assess the long-term efficacy and safety of tumour necrosis factor (TNF) antagonists (infliximab [IFX], adalimumab [ADA] and golimumab) for the treatment of patients…